Kymera completes Phase 2b AD trial enrollment ahead of schedule

June 25, 2026 7:02 AM

Kymera Therapeutics (NASDAQ: KYMR) announced it has completed enrollment in its BROADEN2 Phase 2b clinical trial of KT-621 for moderate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found